Overall rank by patents
#28,149
of 49,997 tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 7 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties).
The verdict
According to USPTO PatentsView, Aspect ranks #28,149 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 7 technology areas.
USPTO PatentsView assignee plate
Corpus R28149 · Foreign Corporation #28,149 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Ascendis Pharma Bone Diseases A/S (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Aspect AI · this assignee
29 score
3D Lighting… · lowest
7 score
What this shows Aspect's Innovation Score is 29.1/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Aspect AI Ltd. is a focused PatentsView assignee: 7 CPC subclasses with 88.9% of grants classified under G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2015. By volume, Aspect sits between Ascendis Pharma Bone Diseases A/S and Astex Pharmaceuticals, Inc..
Aspect AI Ltd. shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Ascendis Pharma Bone Diseases A/S
9 patents
Asclepius (SUZHOU) Technology Company Group Co., Ltd.
9 patents
Asgco Manufacturing, Inc.
9 patents
Asia IC Mic-process, Inc.
9 patents
Assa Abloy High Security Group Inc.
9 patents
Association Francaise Contre LES Myopathies
9 patents
Assoma Inc.
9 patents
Astex Pharmaceuticals, Inc.
9 patents
Aspect AI Ltd.
9 patents
What this shows Aspect holds 9 patents at rank #28,046, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #28,046 in granted patent volume.
Other assignees with the most granted patents in Aspect's primary technology class.
Aspect's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 30th percentile higher than 30% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 11.1% |
| 2016 | 2 | 22.2% |
| 2018 | 1 | 11.1% |
| 2019 | 2 | 22.2% |
| 2020 | 1 | 11.1% |
| 2021 | 1 | 11.1% |
| 2022 | 1 | 11.1% |
Top 7 of 7 technology areas
Overall rank by patents
#28,149
of 49,997 tracked assignees
29.1 out of 100
What to do with this data
Aspect AI Ltd.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.